DNTH as reported
Dianthus Therapeutics, Inc. reported $2.0M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$2.0M
Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied
- Net Income
- −$192M
Net Income · +68% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$156M
Free Cash Flow · +55% year on year · trailing twelve months to Q2 2026
- Op Margin
- −13902%
Op Margin · trailing twelve months to Q4 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $2.0M | n/a | Q4 2025 |
| Net Income | −$192M | +68% | Q2 2026 |
| EPS | −$4.24 | +30% | Q2 2026 |
| Op Margin | −13902% | n/a | Q4 2025 |
| Net Margin | −12724% | n/a | Q4 2025 |
| ROE | −22% | n/a | Q2 2026 |
| ROA | −21% | n/a | Q2 2026 |
| Free Cash Flow | −$156M | +55% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Dianthus Therapeutics, Inc. (DNTH) - Revenue & ProfitRevenue & ProfitDianthus Therapeutics, Inc. (DNTH)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com